glp 1 help with perimenopause GLP-1 Medications & Perimenopause: or Harm? The Complete GLP-1 Guide for

Any papers resulting from these two trials do not appear to be indexed in major global databases like PubMed, and its not clear if they were ever published in peer-reviewed journals

Evidence continues to grow around their long-term health benefitsincluding improved cardiovascular outcomes, protection for the liver and kidneys, and reduced severity of sleep apnea

In a randomized, single-blind, 24-week study, participants assigned to dual therapy of 2 mg weekly of the GLP-1 receptor agonist exenatide (Bydureon, AstraZeneca) and 10 mg daily of the SGLT2 inhibitor dapagliflozin (Farxiga, AstraZeneca) lost more weight than those taking either agent alone or those receiving dapagliflozin and metformin extended-release (Xigduo XL, AstraZeneca) or phentermine/topiramate extended-release (Qsymia, Vivus)

These findings provide insight into the potential benefits of GLP-1 RAs, but they are preliminary and warrant further investigation

Monitor safety and risks proactively : The Veterans Affair study 1 found GLP-1 use was associated with an increased risk of 19 conditions, mainly affecting the digestive and musculoskeletal system